Background. -Atrial fibrillation is the main cause of stroke, but the risk can be reduced, usually with vitamin K antagonists (VKAs) such as warfarin. The RE-LY atrial fibrillation study demonstrated that the rates of stroke and systemic embolism with dabigatran (an oral direct thrombin inhibitor) were similar to or lower than those with warfarin. Aims. -To estimate the cost-effectiveness, from a French payer perspective, of dabigatran (150 or 110 mg bid for patients < or ≥ 80 years, respectively) versus warfarin. Methods. -Cost-effectiveness was modeled using a Markov model in a cohort of 10,000 patients with atrial fibrillation followed over their lifetime. Events accounted for included ischemic stroke, systemic embolism, transient ischemic attack, hemorrhage, myocardial infarction and
Background
Atrial fibrillation (AF) is the most common arrhythmia in France. The incidence increases with age, and 10% of people over 80 years of age have the condition [1] . AF is the main cause of stroke, and as strokes in AF patients are particularly severe and disabling, their prevention is of great importance [2, 3] . Vitamin K antagonists (VKAs) and aspirin are presently the main preventive agents [4] . VKAs have been shown to reduce the risk of stroke by 68% compared with aspirin [5] , but have a narrow therapeutic window of anticoagulation and have many interactions with food and other drugs. If overdosed, VKA administration presents an excess risk of hemorrhage, while protection from stroke is diminished in case of underdosing. Thus, VKAs require regular international normalized ratio (INR) monitoring and dose adjustments to be effective and safe.
Dabigatran is an oral direct thrombin inhibitor that provides stable anticoagulation with a fixed dose and no need for anticoagulation monitoring. It has been marketed since 2008 for the prevention of venous thromboembolic events in patients undergoing scheduled surgery for total knee or hip replacement. The RE-LY study [6, 7] demonstrated that dabigatran is effective in the prevention of thromboembolic events in patients with AF. It compared two doses of dabigatran (110 or 150 mg twice daily [bid]) to warfarin (dosage adjusted on INR). It demonstrated that the rates of stroke and systemic embolism were similar (110 mg bid) or lower (150 mg bid) than those observed in patients treated with warfarin. The risk of major hemorrhage was similar (150 mg bid) or lower (110 mg bid). Although both doses of dabigatran have been approved, the higher dose is recommended for patients < 80 years old and the lower dose for patients aged ≥ 80 years [8] .
The aim of the present study was to assess the costeffectiveness of dabigatran compared with VKAs in patients with AF using a Markov model. Following the recommendations, the model evaluated dabigatran 150 and 110 mg bid doses for patients aged < 80 and ≥ 80 years, respectively.
Methods

Patient population
We considered a cohort of 10,000 patients with AF followed for their remaining lifetime to capture the lifelong consequences of stroke and hemorrhage. The population matched the criteria of the RE-LY trial [6, 7] . Patients had diagnosed AF and at least one of the following characteristics: at least one additional risk factor for stroke or embolism (as defined by the CHADS 2 score risk stratification scheme) or impaired left ventricular ejection fraction. They were eligible for anticoagulation treatment but were not taking concomitant anticoagulation treatment. The CHADS 2 score ranged from 0 to 6 (mean 2.1). Twenty percent of patients had a history of previous stroke or transient ischemic attack. The mean age of the patients was 69 years and 65% were men.
Model structure
The model is an adaptation of Sorensen et al.'s costeffectiveness model to the French setting. It has been fully described elsewhere [9, 10] . The cost-effectiveness of dabigatran was modeled with a 3-month cycle Markov model. The different events taken into account were: ischemic stroke, intracranial hemorrhage, hemorrhagic stroke (all fatal, independent, moderate disability and totally dependent); systemic embolism, extracranial hemorrhage, acute myocardial infarction (all fatal and non-fatal); transient ischemic attack and death from other causes. At each cycle of the model, patients could experience one of the precited clinical events or remain unchanged in their current health state. A 3-month cycle length was used because it is unlikely that patients would experience more than one major event during any 3-month period. The consequences of the clinical events were disability as defined by the modified Rankin Score (after a stroke) or Glasgow Outcomes Scale (after intracranial hemorrhage), death, reduction in quality of life, changes in risks of future events and treatment status. Fig. 1 presents a simplification of the Markov model. Severe hemorrhagic events could result in discontinuation of current treatment and a switch to aspirin. Patients could also discontinue for other reasons, clinical or not. A first ever stroke resulted in an increase of the CHADS 2 score of two points. The score remained unchanged after a recurrent stroke. It increased by one point when patients passed the age of 75 years. The risk of extracranial hemorrhage doubled when patients passed 70 years of age [11] .
The model assumed that patients not discontinuing remained adherent to anticoagulation treatment and the relative treatment effect remained constant over time.
Patients discontinuing treatment received no further clinical benefit.
Future costs and outcomes were discounted at 4% per annum to convert them to present day equivalents according to the recommendations of the Haute Autorité de santé (HAS; the French National Authority of Health) [12] .
Model scenarios
In RE-LY, 64% of patients under VKAs were at their INR target, whereas in France, published data showed that only 46% are at target [13] . Moreover, two other publications [14, 15] have suggested that patients presenting similar profiles to RE-LY patients with AF received other anticoagulant agent than VKAs or were not treated, leading to less efficacious stroke prevention. For this reason, we modeled two scenarios: a ''trial-like'' scenario (where patients received dabigatran or warfarin) and a ''real-life'' scenario (where patients received dabigatran, a VKA, aspirin or no anticoagulant). In the ''real-life'' scenario, the relative efficacy of dabigatran versus VKAs was the same as in the RE-LY trial and was derived from indirect comparisons with aspirin or no treatment [16] . The percentages of patients taking VKAs, aspirin or untreated were derived from Cohen et al. [15] , while data from Cegedim Strategic Data [14] were used in a sensitivity analysis.
Data sources
Probabilities of events
Annual probabilities of events in the VKA arm and the relative risks (RRs) of dabigatran 110 and 150 mg bid, aspirin and no treatment versus VKAs were taken from the original model [9] . All-cause mortality data adjusted for age were obtained from the French Institute of Health and Medical Research [17] . Baseline characteristics of the patient population in the model matched the CHADS 2 distribution of patients entering into the model was the same as observed in RE-LY. Because fluindione is the most frequently used VKA in France, we assumed that outcomes from RE-LY with warfarin could be transposed.
Utilities
Since no utility values were available in the French context, utility values for each disability level and utility decrements due to clinical events were taken from the published literature [18, 19] . The effective decreases in utility at the time of the event were 0.139 for stroke, 0.120 for systemic embolism, 0.181 for intracranial hemorrhage, 0.103 for transient ischemic attack and 0.125 for myocardial infarction. The level of impairment corresponding to the patient's functional status was also included: 0.65 for independent patients with stroke history, 0.46 for moderately dependent patients and 0.30 for totally dependent patients.
Resource use and costs
The baseline scenario considered only direct medical expenditures covered by the National Sickness Fund (NSF), thus adopting a health services payer perspective. The NSF covers all healthcare services expenditures (acute hospital care, ambulatory services, drug treatment, rehabilitation and healthcare delivered in ''nursing home''-type facilities. The French ''départements'' (France is administratively divided into 96 ''départements'') are responsible for partially covering expenditures related to functional dependency of patients, through payments adjusted on the degree of dependency. Finally, in nursing homes, patients have to pay out-of-pocket accommodation. HAS recommends that all direct expenses by all potential payers are taken into account when performing a cost-effectiveness analysis, therefore, a secondary scenario was considered including payments from the social services of the departments and out-of-pocket money from patients. All costs have been updated to the year 2011 according to the price index of medical services. All costs are summarized in Table 1 [20] [21] [22] [23] [24] .
Direct medical expenditures
Anticoagulation treatment costs. The most frequently prescribed VKA in France is fluindione with a recommended dose of 1 pill per day. Based on the French register of pharmaceutical specialities, Vidal, the daily treatment cost of fluindione was D0.13.
The tariff for INR monitoring was obtained from the French NSF website [21] and was D14.04. This rate was adjusted to take into consideration the fact that in one-third of cases, the INR would be included in a bundled rate for multiple blood parameter testing, thus at a cheaper rate; and in two-fifths of cases, the test would require a nurse home visit for the blood sample. A final adjusted unit cost of D11.17 was applied. The annual cost of treatment with a VKA therefore reached D181.49 (i.e. 365 × 0.13 D + 12 × 11.17 D). According to the French National Agency for Medicines and Health Products Safety [13] , French patients under VKAs are out of target INR 54% of the time, which suggests that they may require more INR tests to adjust the posology. In the one-way sensitivity analysis, we assumed that, in real practice, French patients would require at least six more INR tests, thus leading to an annual cost of treatment of D248.51 (i.e. 365 × 0.13 D + 18 × 11.17 D).
The daily cost for dabigatran 110 or 150 mg bid was D2.53 (Table 1) . No monitoring costs were considered. In the case of AF, the European Society of Cardiology recommends aspirin [25] if VKAs are not tolerated. We assumed a 325 mg daily dose. Based on the French register of pharmaceutical specialities, Vidal, the daily cost of this dosage was D0.09.
Costs associated with stroke. Stroke costs comprised two major items: the cost of initial hospitalization and subsequent costs, distinguishing the first year after stroke from following years. The number of initial hospitalizations for stroke and the diagnosis-related group (DRG) in which they were classified were selected from the French 2009 National Hospital Database (Programme de médicalisation des systèmes d'information [PMSI] ). This database records all admissions to public and private hospitals in a given year. Stays were selected on their main diagnosis based on 10th revision of the ICD-10 codes: hemorrhagic stroke (I60-I62), ischemic stroke (I63), transient ischemic attack (G45). In the French classification, DRGs are split into four levels based on the severity of comorbidities. AF is a level-2 comorbidity, so we selected only DRGs with a minimum level of two. For each stay, the national 2011 tariff of the DRG was applied: the costs of the initial hospitalization were D7108, D7240 and D5429 for ischemic stroke, hemorrhagic stroke and transient ischemic attack, respectively (Table 1) .
Follow-up costs during the first year after stroke were derived from the ECIC study [26] . In this study, costs were differentiated by resulting disability level (independent, moderate disability and totally dependent) 18 months after patients experienced a stroke. Initial hospitalization costs reported in that study were not taken into account, since they were obtained separately. The cost was calculated relative to the first 12 months and included nursing home care. The annual mean costs of independent patients, those with moderate disability and dependent patients were D4632, D14,015 and D29,582, respectively.
Follow-up costs in subsequent years were based on data from Spieler et al. [23] . The direct medical costs of independent patients, those with moderate disability and totally dependent patients living at home were D233, D369 and D719 per month, respectively.
Costs associated with myocardial infarction or major hemorrhage. Only the cost of the initial hospitalization was taken into account. The initial hospitalization cost was calculated using 2009 PMSI (ATIH) data and the national 2011 tariff. Stays were selected when the main diagnosis was that of myocardial infarction (ICD-10: I21 and I22) or major hemorrhage (K625, K920, K921, K922, R041, R042, R048, R049, R31 and R58). Only DRGs with a minimum severity level of two were selected. The resulting cost was applied to each event.
Cost of institutionalization. After Thus, EPHADs and USLD are the dominant setting and we used tariffs and costing information available for these settings, although they are less costly than the two other, more specialized settings. USLDs and EPHADs are financed through a daily rate for healthcare services, covering physician and nursing care costs and funded by the NSF. There is a daily rate to pay for the burden of dependency of elderly people, funded by the social budget of departments, and one for accommodation, paid by the residents. In the absence of national data sources on actual tariffs for different settings, we used survey data [24] , which provide costs for the first two financing sources. The mean cost for healthcare services was D24.50 per day (range D19.90-29.20). The mean expenditure of departments was D12.70 per day (range D11.30-13.30) [24] . According to the Inspectorate General for Social Affairs [28] , out-of pocket charges for patients in EPHADs was D60.00 per day (range D50.00-97.70).
Using existing sources [29, 30] , we estimated that 35.2% of post-stroke dependent patients were admitted into a nursing home. Thus, the extra cost of D24.50 per day for healthcare services was added to other direct medical costs in the same proportion. The costs to cover dependency and the out-of-pocket costs for patients were included in the all-payer analysis (D72.70 per day).
Analyses. The base-case model compared dabigatran
to ''trial-like'' warfarin use. Model outcomes were the number of events, quality-adjusted life years (QALYs), total costs and incremental cost-effectiveness ratios (ICERs).
One-way sensitivity analyses were computed on the basecase to identify key determinants of cost-effectiveness by varying parameters individually. A probabilistic sensitivity analysis was conducted to compute a cost-effectiveness acceptability curve. The cumulative effect of varying all model parameters within their statistical distributions, based on 95% confidence intervals, was tested. For this analysis, 1000 trials were run, where each input was sampled at random from probability distribution functions assigned to each variable. Distributions were defined by means and reported or calculated standard errors. We assumed that probabilities and utilities had beta distributions (bounded between 0 and 1) and relative risks (RRs) had log-normal distributions and event costs had gamma distributions (bounded by 0 with a right skew) [31] . The model was computed in Microsoft Excel 2003.
Cost-effectiveness
thresholds. Thresholds of D24,000 and D36,000 were selected based on the published thresholds of £20,000 and £30,000 in the United Kingdom [32] , since there is no defined threshold in France. We updated the conversion of the UK threshold using the exchange rate of £0.827 to 1 D observed on March 2014 and rounded the conversion results.
Results
Base-case analysis
Compared with ''trial-like'' warfarin, patients treated with dabigatran were predicted to experience fewer ischemic strokes, systemic embolisms, transient ischemic attacks and intracranial hemorrhages or hemorrhagic strokes, but more extracranial hemorrhage and myocardial infarctions ( Table 2) .
Compared with ''real-world'' prescribing, patients treated with dabigatran were predicted to experience fewer ischemic strokes, systemic embolism, transient ischemic attacks, intracranial hemorrhage or hemorrhagic strokes and extracranial hemorrhage, but more myocardial infarctions ( Table 2 ).
These differences in the numbers of clinical events resulted in an increase in QALYs for patients treated with dabigatran (7.94) versus ''trial-like'' warfarin (7.70) and ''real-world'' prescribing (7.56) . The results are presented in Table 3 , along with detailed costs and ICERs for the different scenarios. Follow-up costs represented the largest share of the costs (47% for dabigatran; 62% for ''triallike'' warfarin and ''real-world'' prescribing).The ''payer perspective'' ICERs for dabigatran versus ''trial-like'' warfarin and ''real-world'' prescribing were D15,838/QALY and D7473/QALY, respectively ( Table 3) . Considering the ''allpayer perspective,'' these figures were D13,568/QALY and D5663/QALY, respectively.
One-way sensitivity analyses
The most influential variables in our model (payer perspective, ''trial-like'' warfarin) were the RR of ischemic stroke with dabigatran and the time horizon of the model (Fig. 2) . Using a shorter time horizon of 10 years increased the ICER to D33,145/QALY. To a lesser extent, the RRs of intracranial hemorrhage and hemorrhagic stroke, the discounting rate and warfarin monitoring cost also affected the ICER (Fig. 2) . Only the variables with the greatest ability to influence the results are presented in Fig. 2 .
The impact of the proportion of different treatments in the ''real-world prescribing'' scenario was also tested, comparing the proportions observed in Cohen et al. [15] (VKA: 78.7%; aspirin: 20.7%; no treatment: 0.6%) to those observed in Cegedim Strategic Data [14] (VKA: 59%; aspirin: 22%; no treatment: 19%). Increasing the number of patients with no treatment and decreasing the number of patients treated by VKAs provided a slightly more favorable ICER (D4863 vs D7473/QALY).
Probabilistic sensitivity analysis
The results of the probabilistic sensitivity analysis showed that the ICER of dabigatran was < D24,000 in 71% of the simulations when compared with ''trial-like'' warfarin and in 100% of cases when compared with ''real-world'' prescribing ( Fig. 3 ). It was < D36,000 in 92% and100%, respectively, of simulations. 
Discussion
This modeling study evaluated the cost-effectiveness of dabigatran compared with ''trial-like'' warfarin and ''real-world'' prescribing, using dabigatran 150 mg bid for patients < 80 years of age and 110 mg bid for patients aged ≥ 80 years. In the base-case scenario (payer perspective), the ICER of dabigatran compared with ''triallike'' warfarin was D15,838/QALY; this fell to D7473/QALY when dabigatran was compared with ''real-world'' prescribing. In this latter case, the relative clinical effectiveness of dabigatran was enhanced because a significant number of patients did not receive adequate anticoagulation, thus incurring higher risks than those observed in RE-LY. When an ''all-payer'' perspective was adopted, the ICERs were even more favorable: each ICERs was decreased by approximately 2000 D/QALY. We have compared our results to published costeffectiveness studies in other countries. Twelve studies with single technology assessments of dabigatran compared with VKAs covering eight countries were identified in PubMed. Among these, six studies [33] [34] [35] [36] [37] [38] adapted the model from Sorensen et al. [10] and assessed the cost-effectiveness of dabigatran 150 or 110 mg bid according to age. The other studies assessed different treatment courses, including assessing 150 and 110 mg bid separately, comparing dabigatran to warfarin, aspirin and clopidogrel, or focusing on sub-groups based on age or risk level measured by CHADS 2 score [39] [40] [41] [42] [43] .
A brief comparison of the studies showed higher ICERs in studies from USA (from D9364/QALY for 150 mg bid compared with warfarin [39, 40] to D113,400/QALY for 110 mg bid compared with warfarin [43] ). A major differentiating factor was the daily price of dabigatran, which ranged from D5.20 to D7.20 in USA studies [39, 41] and from D2.45 (Canada: ICER = D13,987/QALY [10] ) to D3.20 (Switzerland: ICER = D8213/QALY [37] ) in other countries. ICERs for studies that based dabigatran dose on age and were based on trial data and had similar costing methods ranged from D6002 per QALY in UK [35] to D17,581 per QALY in Spain [34] . Thus, our results in France are in the range of the results found in other European countries. The two main economic factors that contributed to such variability were, firstly, the cost of treatment with dabigatran relative to the cost of monitoring INRs with VKAs and, secondly, the relative costs of stroke and prevention.
Study limitations
The study was based on the only available published clinical trial comparing dabigatran with warfarin. We assumed that fluindione would have similar efficacy to warfarin in a comparative trial with dabigatran. To cope with both of these limitations, we used a deterministic (one-way) analysis and a probabilistic sensitivity analysis, which showed that these ICERs were robust to uncertainty and variability in the model parameters, including outcomes. Assuming a willingness-topay threshold of around D24,000, the ICERs were below this threshold in all but the most conservative scenarios against dabigatran (i.e. short time horizon and upper limit of the 95% confidence intervals for RRs of ischemic stroke and intracranial hemorrhage). Nevertheless, the certainty with which dabigatran was judged to be cost-effective appeared at acceptable levels, with 71% and 100% of simulations for ''trial-like'' warfarin and ''real-world'' prescribing, respectively, below the D24,000 threshold, and 92% and 100%, respectively, below the D36,000 threshold.
Results are particularly sensitive to the cost of monitoring patients treated with VKAs. In France, the overall performance in general practice is low when compared with monitoring in the RE-LY trial. Thus, an important issue is how much investment is needed in France to get closer to optimal management, which would increase the total cost of VKA treatment but also its effectiveness. Moreover, in real life, compliance issues may arise with dabigatran because of twice daily administration and the absence of monitoring. Also, we have not included costs of follow-up post-acute myocardial infarction in the model, which results in improving the ICER for dabigatran because of an excess event rate with this treatment. However, the rate of acute myocardial infarction is a third the rate of strokes and this has a limited impact on the ICER.
We also assumed that treatment efficacy was sustained beyond the trial period, as there is no evidence that the efficacy of anticoagulation would change in adherent patients. We used dropout rates from RE-LY for both treatments, which may prove to be untrue in real life. Finally, our estimation of the cost of dependent patients in nursing homes is not based on observed resource use; it may be underestimated, since we have focused only on the ones with the less intensive care for handicapped patients.
Conclusion
This modeling study suggests that the use of dabigatran for stroke prevention in French AF patients is likely to be costeffective according to usually accepted thresholds.
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